| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2015: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Vascular endothelial growth factor (VEGF) is considered to be deeply related to the occurrence of exudative age-related macular degeneration (AMD). Currently, intravitreal injection of anti-VEGF drugs is effective for the disease. AMD with occult choroidal neovascularization (CNV), which is a type of AMD, has CNV under the retinal pigment epithelium. AMD with occult CNV is capable of being divided into two groups according to its responsiveness to anti-VEGF drugs. One is the CNV that have good response to the drugs and the other is the CNV that is resistant to the drugs. We analyzed the choroidal thickness of each case with occult CNV and assessed prospectively if the choroidal thickness has relevance to the effectiveness of the treatment. As a result, we found the case with thick choroid responded to the treatment better than the case with thin choroid. In conclusion, it is suggested that VEGF is less involved in the pathogenesis of AMD with thin choroid than that with thick choroid.
|
